BioSpace News Archive

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced positive results from the phase 3 KONFIDENT clinical trial demonstrating statistically and clinically significant efficacy of sebetralstat as oral on-demand therapy for hereditary angioedema (HAE).

First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”) today announced that James Sapirstein, Chairman and CEO of First Wave BioPharma, will present at the BIO CEO & Investor Conference, which is planned for February 26-27, 2024, at the Marriott Marquis in New York City.

Eyenovia, Inc. announced that the company’s facility in Redwood City, California successfully completed FDA inspection for approval as a commercial manufacturing facility.

Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, today announced the first patient dosed in the combination arm of the Phase 1/2 ABILITY (ABeta-only IL-2 ImmunoTherapY) study evaluating MDNA11, a long-acting, “beta-enhanced not-alpha” interleukin-2 (IL-2) super-agonist, with KEYTRUDA® (pembrolizumab).

TETROUS, INC. unveils the addition of EnFix TAC to its family of EnFix™ demineralized bone allograft implants for use in rotator cuff surgery.

Transposon Therapeutics announced final results from its Phase 2 study of TPN-101 for the treatment of progressive supranuclear palsy.

Precision BioSciences, Inc. today announced that Naresh Tanna, Chief of Staff to the CEO, has been promoted to Vice President of Investor Relations.

Tonix Pharmaceuticals Holding Corp. today announced that it has engaged Rho, Inc. (Rho), a global contract research organization (CRO), to support Tonix’s preparation and planned submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the management of fibromyalgia.

RAPT Therapeutics, Inc. today announced the appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations.

Ace Vision Group, Inc., an emerging medical device company at the forefront of pioneering rejuvenation therapy for the aging eye and presbyopia, announced that it has named Val Kolesnitchenko, MD, as Chief Scientific Officer.